EHA2025
MILAN
We are excited to be at EHA2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.
To learn more about our cell therapy abstracts and data, please visit the congress website.
Real-World Effectiveness and Safety Outcomes Among Key Subgroups of Second-Line Axicabtagene Ciloleucel for Patients with Relapsed/Refractory Large B-Cell Lymphoma
A Phase 1 Study of KITE-363 Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B-Cell Lymphoma
*Kite collaboration
Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma: Updated Results from iMMagine-1
Five-Year Survival Outcomes of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Brexucabtagene Autoleucel in ZUMA-3
Treatment Patterns and Economic Outcomes in Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in the US: A Real-World Claims Database Analysis
Real-World Outcomes of Brexucabtagene Autoleucel in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review and Meta-Analysis
Understanding Caregiver Challenges in Multiple Myeloma: A Systematic Literature Review of the Qualitative and Quantitative Literature
Health Impact of Chimeric Antigen Receptor T-Cell Vein-to-Vein Time in Second-Line Large B-Cell Lymphoma Patients: An Exploratory Modelling Analysis for Italy
Cost-Effectiveness of Real-World Axicabtagene Ciloleucel Use in Relapsed/Refractory 2L LBCL Based on a Multi-Center US Registry
Prognostic Value of Circulating Tumor DNA Detection by PhasED-Seq After Axicabtagene Ciloleucel Therapy in Relapsed/Refractory Large B-Cell Lymphoma
*Kite collaboration
KTE-X19 in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia in Chinese Population: A Phase 2 Multicenter Study
The Italian Commercial Axi-Cel Manufacturing Performance: A Retrospective Analysis of an Efficient and Reliable Process Over Time
Clinical, Economic, and Humanistic Outcomes of First-line High-Risk Large B-Cell Lymphoma: A Series of Systematic Literature Reviews
A case-based approach to the evolving treatment landscape in R/R lymphomas
Join Prof Stefano Luminari , Dr Lorenzo Falchi, Dr Mary Ann Anderson and Dr Martina Pennisi to explore the pathway to a potential cure in R/R Lymphomas. Through a series of interactive case studies, they will explore some best practices around referral for CAR T, as well as how best to navigate conversations with patients and caregivers.
Join us on:
Saturday 14 June, 10:00-11:30 CEST
In Coral Hall 2 and online
Agenda
Professor Stefano Luminari
University of Modena and Reggio Emilia, AUSL IRCCS, Reggio Emilia, Italy
10:00 AM - 10:10 AM CEST
Welcome and introduction
Dr Lorenzo Falchi
Memorial Sloan Kettering Cancer Center, New York, USA
10:10 AM - 10:35 AM CEST
Hope for the best, plan for the worst:
The patient with DLBCL at high risk of relapse
Dr Mary Ann Anderson
Peter MacCallum Cancer Centre, Melbourne, Australia
10:35 AM - 11:00 AM CEST
Age is not a barrier: The older patient with comorbidities
Dr Martina Pennisi
Istituto Nazionale dei Tumori, Milan, Italy
11:00 AM - 11:20 AM CEST
Timing is of the essence: The patient with MCL on a BTKi
All, facilitated by Professor Stefano Luminari
11:20 AM - 11:30 AM CEST
Q&A, summary and close
MEET THE FACULTY
Professor Stefano Luminari
University of Modena and Reggio Emilia, AUSL IRCCS, Reggio Emilia, Italy
Professor Stefano Luminari is Full Professor of Medical Oncology at the University of Modena and Reggio Emilia and is head of the Lymphoma Research Unit of the Reggio Emilia National Research Hospital. His clinical activity is strictly integrated with his teaching and research activity and is mainly dedicated to the diagnostic, clinical and therapeutic management of patients with lymphoproliferative diseases. Prof. Luminari’s research activity is highly focused on clinical research in malignant lymphomas. In particular, he is an expert in biomarkers and prognostic studies, in Phase 2 and 3 clinical trials, and in population based studies. He is active member of the Fondazione Italiana Linfomi, the most important cooperative group for lymphoma research in Italy and member of the board of directors of the organisation. His research topics include indolent lymphomas, in particular follicular lymphomas, aggressive lymphomas (mainly elderly patients) and the use of FDG-PET in lymphomas.
Dr Lorenzo Falchi
Memorial Sloan Kettering Cancer Center, New York, USA
Dr Lorenzo Falchi earned his MD degree Cum Laude and a board certification in Medical Oncology Cum Laude at the University of Perugia, Italy. Subsequently in the USA, he completed a postdoctoral fellowship at MD Anderson Cancer Center in Houston, TX, medicine residency at Yale-New Haven Hospital in New Haven, CT, and a Hematology/Oncology fellowship at Columbia University Irving Medical Center in New York, NY. He is board certified in Internal Medicine, Hematology and Medical Oncology. He currently holds a dual appointment as Assistant Attending in the Lymphoma Service and Cellular Therapy Service at Memorial Sloan-Kettering Cancer Center, and is an Assistant Professor of Medicine at Weill Cornell Medical College, both in New York, NY.
Dr Falchi’s areas of interest include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. His current research is focused on the use of immunotherapy for the treatment of patients with B-cell NHL through the conduct of clinical and translational studies. He is the lead investigator in multiple national and global immunotherapy trials for patients with B-cell NHL and has published widely.
Dr Falchi is Co-Editor-In-Chief of Oncoimmunology and is a member of the Editorial Board for Blood Advances. In addition, Dr Falchi serves as peer-reviewer for numerous high-profile journals, such as JAMA, Blood and JAMA Oncology. He has been the recipient of several awards including the Leukemia & Lymphoma Society Scholar in Clinical Research award, the Lymphoma Research Foundation Career Development award, and the Memorial Sloan-Kettering Steven A. Greenberg Lymphoma Research award. He serves on multiple committees of the American Society of Clinical Oncology and Society for Immunotherapy of Cancer and is an active member of multiple scientific societies, including the American Society of Hematology, the American Society of Clinical Oncology, American Medical Association, the American Association for Cancer Research.
Dr Mary Ann Anderson
Peter MacCallum Cancer Centre, Melbourne, Australia
Associate Professor Anderson has been a practising clinical haematologist since 2012. She currently practices at both The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre in Melbourne – where she leads the Low-Grade Lymphoma and Chronic Lymphocytic Leukaemia Disease Stream. She is a foundation member of the CART consultant group at the Peter MacCallum Cancer Centre, having joined the team at the inception of the unit in 2019. Dr Anderson obtained her PhD from the University of Melbourne in 2017 where she undertook extensive clinical and laboratory studies of a novel approach to treating B cell malignancies by harnessing apoptotic cell death with the agent now known as venetoclax. Since completion of her PhD Dr Anderson has continued her studies into the mechanisms by which B cell malignancies evade targeted agents to develop therapeutic resistance.
Dr Martina Pennisi
Istituto Nazionale dei Tumori, Milan, Italy
Dr Martina Pennisi graduated in Haematology in 2018 at the University of Milan. During 2019–2020, she worked as a research fellow of the University of Milan at Memorial Sloan Kettering Cancer Center in New York NY, USA. She has been working in the Haematology Division at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan since 2017, and in the inpatient ward since 2020. Her clinical and scientific interests focus on immune and cellular therapies, including chimeric antigen receptor T cells for the treatment of patients with lymphoma and myeloma and allogeneic stem cell transplantation. Dr Pennisi has been the author or co-author of more than 40 publications.
This non-promotional educational symposium, intended for healthcare professionals only, is organised and fully funded by Kite, a Gilead Company, through Gilead Sciences Europe Ltd., and may include discussion of investigational therapies and/or indications/uses. These have not been approved by regulatory authorities and their safety and efficacy for use in humans have not been established yet.
How is CAR T revolutionising the treatment landscape in R/R multiple myeloma
Join Dr Benedetto Bruno and Dr Doris Hansen who will be discussing current unmet needs in multiple myeloma and the rapidly evolving role of CAR T-cell therapy. The session includes interactive exchange and will include live participation.
Join us on:
Friday 13 June, 10:00-11:30 CEST
In Coral Hall 7 and online
Agenda
Chair: Professor Benedetto Bruno
Università di Torin, Torino, Italy
10:00 AM - 10:05 AM CEST
Welcome and introductions
Dr. Noopur Raje
Harvard University, Boston, MA, USA
10:05 AM - 10:30 AM CEST
Unmet needs in Multiple Myeloma
Dr. Doris Hansen
Moffitt Cancer Center Tampa, FL, USA
10:30 AM - 10:55 AM CEST
The Role of CAR T-cell Therapy in Multiple Myeloma
Professor Aurore Perrot
Université de Toulouse, Toulouse, France
10:55 AM - 11.25 AM CEST
The Future of CAR T-cell Therapy in Multiple Myeloma
Chair: Professor Benedetto Bruno
Università di Torin, Torino, Italy
11:25 AM - 11.30 AM CEST
Recap and Close
MEET THE FACULTY
Professor Benedetto Bruno
Università di Torin, Torino, Italy
Benedetto Bruno, MD, PhD, is Associate Professor of haematology at the Department of Molecular Biotechnology and Health Sciences – School of Medicine - University of Turin, Italy - and Program Head at the Bone Marrow Transplantation Unit of the A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Turin, Italy. Following medical training at the University of Pavia, Italy, Dr Bruno worked as a resident in haematology at the University of Turin before taking up, in 1995, a fellowship at the Department of Transplantation Biology at the Fred Hutchinson Cancer Research Centre, Seattle, WA, USA. He passed the United States Medical License Examination in 1996. He then returned to Italy in 2000 when he received a doctorate in experimental haematology from the University of Genoa. Dr. Bruno has a particular interest in the role of autologous and allogeneic stem cell transplantation, and cell therapies in the treatment of haematological disorders, Dr. Bruno has received several awards, including the International Cancer Technology Transfer Award from the International Union Against Cancer, Geneva, Switzerland.
Dr. Noopur Raje
Harvard University, Boston, MA, USA
Noopur Raje, MD, is the Director of the Centre for Multiple Myeloma in the Mass General Cancer Centre. Dr Raje earned her MD from BJ Medical College, University of Pune in Pune, Maharashtra, India. After completing her residency at Mass General and a fellowship at Dana-Farber Cancer Institute, she returned to Mass General where she established her own lab to investigate multiple myeloma. Her lab comprises a translational research program to evaluate new therapies with a focus on myeloma bone disease biology. Dr Raje's work explores the bone marrow microenvironment and new targets for treatments that will stop tumour growth. Her research also strives to understand the factors that cause bone disease in patients with myeloma. Dr Raje is a member of the International Myeloma Working Group and National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines Committee for Multiple Myeloma. In 2010, she received the Clafin Distinguished Scholar award at Mass General. In 2013, she was named the first incumbent of the Rita M Kelley Chair in Oncology at Mass General. In 2017, she received the Leukaemia and Lymphoma Society Clinical Scholar Award.
Dr. Doris Hansen
Moffitt Cancer Center, Tampa, FL, USA
Dr. Hansen is an Assistant Member/Professor in the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a practicing haematologist integrated in the Immune Cell Therapy (ICE-T) Program at Moffitt Cancer Centre and the University of South Florida/Morsani College of Medicine. Her clinical and research interests include utilizing autologous transplantation and cellular immunotherapies to treat and improve outcomes for patients with multiple myeloma. Dr. Hansen's research interest focuses on characterizing both clinical and patient-reported outcomes among individuals with multiple myeloma receiving immunotherapies, as well as identifying the impact of inflammation and immunity on
toxicity and efficacy in this patient population.
Professor Aurore Perrot
Université de Toulouse, Toulouse, France
Aurore Perrot, MD, PhD, is an Associate Professor in Haematology at the University of Toulouse, France. Dr Perrot received her medical degree from the Henri Poincaré University, Nancy, France, in 2009 and completed her PhD at the University of Lorraine, Lorraine, France, in 2015. Dr Perrot then served as an MCU-PH at the University of Lorraine until 2019. Dr Perrot specialises in the treatment of patients with newly diagnosed multiple myeloma. Dr Perrot has been involved in a number of clinical trials investigating novel antibody therapies for multiple myeloma treatment in addition to genomics studies researching predictive markers which are significant in the treatment of multiple myeloma.